RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

If I were a potential RD partner, I'd be proposing a more backloaded deal than Cortex would like. In other words, putting more milestone weight on the clinical advent of CX-717 IV, or of another compound from your list. The IV form of CX717 will start its own patent clock, and I don't think the 3 months at high doses of CX717 primate artifact finding, which spooked Psychiatry, is going to be an insurmountable obstacle for one-use CX717, oral or IV, when assessed by the Analgesia division.

But then again, I thought the SA study would be a quick and easy read of CX717 in that disorder, so......

NeuroInvestment